Active — Not RecruitingNot Applicable

Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs

Kazakhstan120 participantsStarted 2024-12-18

Plain-language summary

This clinical study aims to improve the diagnosis and treatment of cardiovascular diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1). These medicines are called incretin-based therapies and include GLP-1 receptor agonists and a newer dual therapy that targets both GIP and GLP-1 receptors. Such medications have already shown benefits in lowering blood sugar, reducing body weight, improving blood pressure, and lowering the risk of serious heart complications. Cardiovascular diseases and diabetes are among the most common health problems in Kazakhstan. Many patients remain undiagnosed or receive treatment only after their condition becomes severe. This study seeks to address these challenges by testing how well dual incretin therapy works in improving heart health, blood sugar control, and overall metabolic status in adults who have both chronic heart failure and type 2 diabetes. Participants in the study will receive a detailed health evaluation at the beginning, including heart tests, blood work, and genomic profiling. Genomic testing will help researchers understand whether certain genetic features affect how patients respond to this therapy. After the initial assessment, participants will start treatment with a GIP/GLP-1 receptor agonist and will be monitored every few months for a total of 40 weeks. During these visits, their heart function, blood sugar levels, weight, and other health indicators will be checked to ensure both safety and effectiveness. The main hypothesis of the study is that dual incretin therapy will improve heart function, reduce cardiometabolic risks, and show measurable benefits in patients with both chronic heart failure and type 2 diabetes. The study also assumes that a person's genetic profile may influence how well they respond to treatment. By the end of the project, researchers hope to better understand how these medications work in the Kazakhstani population and to use these findings to support more personalized, effective, and modern approaches to treating cardiovascular diseases.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chronic heart failure with preserved ejection fraction (left ventricular ejection fraction not ≤ 45%) * Type 2 diabetes mellitus (T2DM) with HbA1c level between ≥7.0% and ≤10.5% * Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy) * Stable body weight (±5%) for at least 3 months prior to screening * Body mass index (BMI) ≥ 25 kg/m² * Possible inclusion of patients with chronic pancreatitis in remission * Aged 18 years or older, and not older than 75 years * Both male and female participants Exclusion Criteria: * Type 1 diabetes mellitus * Exacerbation of chronic pancreatitis * Acute pancreatitis * Proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy * History of bariatric (weight-loss) surgery or conditions associated with delayed gastric emptying * Acute or chronic hepatitis * Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m² * Myocardial infarction or stroke within the past 2 months * Medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) in the participant or a first-degree relative * Use of any other antidiabetic medications (except metformin and/or sulfonylureas and basal insulin) within the past 3 months * Use of weight loss medications, including over-the-counter drugs, within the past 3 months * History of significant active or unstable major depressive disorder (MDD) or other severe psychi…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in NT-proBNP levels from baseline to Week 24

Timeframe: Baseline to Week 24

Trial details

NCT IDNCT07303556

SponsorNazarbayev University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-01

View on ClinicalTrials.gov More Heart Failure trials